{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:54:42Z","timestamp":1794002082497,"version":"4.8.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"DOI":"10.1186\/s13148-025-01894-0","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T08:51:32Z","timestamp":1749718292000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A multi-omics prognostic model of cuproptosis affects the prognosis of stomach adenocarcinoma"],"prefix":"10.1186","volume":"17","author":[{"given":"Yinying","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangwei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danfeng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meichen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyun","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enxiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"issue":"49","key":"1894_CR1","doi-asserted-by":"publisher","first-page":"e32228","DOI":"10.1097\/MD.0000000000032228","volume":"101","author":"H Gao","year":"2022","unstructured":"Gao H, Li L, Geng K, Teng C, Chen Y, Chu F, Zhao Y. Use of proton pump inhibitors for the risk of gastric cancer. Medicine (Baltimore). 2022;101(49):e32228.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"1894_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.34172\/mejdd.2022.251","volume":"14","author":"A Hormati","year":"2022","unstructured":"Hormati A, Hajrezaei Z, Jazi K, AslaniKolur Z, Rezvan S, Ahmadpour S. Gastrointestinal and pancratohepatobiliary cancers: a comprehensive review on epidemiology and risk factors worldwide. Middle East J Dig Dis. 2022;14(1):5\u201323.","journal-title":"Middle East J Dig Dis"},{"key":"1894_CR3","doi-asserted-by":"publisher","first-page":"892468","DOI":"10.3389\/fpubh.2022.892468","volume":"10","author":"Y Hui","year":"2022","unstructured":"Hui Y, Tu C, Liu D, Zhang H, Gong X. Risk factors for gastric cancer: a comprehensive analysis of observational studies. Front Public Health. 2022;10:892468.","journal-title":"Front Public Health"},{"issue":"4","key":"1894_CR4","first-page":"206","volume":"35","author":"S Singh","year":"2022","unstructured":"Singh S, Surendran S, Yacob M, Paul N, Samarasam I. Impact of Covid-19 pandemic on upper gastrointestinal cancer services: experience from an oncosurgical unit. Natl Med J India. 2022;35(4):206\u20139.","journal-title":"Natl Med J India"},{"key":"1894_CR5","first-page":"14","volume":"5","author":"S Mohammed Asiri","year":"2022","unstructured":"Mohammed Asiri S, Levina A, New EJ, Lay PA. Investigations of cellular copper metabolism in ovarian cancer cells using a ratiometric fluorescent copper dye. J Biol Inorg Chem. 2022;5:14.","journal-title":"J Biol Inorg Chem"},{"issue":"50","key":"1894_CR6","doi-asserted-by":"publisher","first-page":"15766","DOI":"10.1021\/acs.langmuir.2c02667","volume":"38","author":"H Lv","year":"2022","unstructured":"Lv H, Zhu Y, Xue J, Jia X, Chen J. Targeted drug delivery system based on copper sulfide for synergistic near-infrared photothermal therapy\/photodynamic therapy\/chemotherapy of triple negative breast cancer. Langmuir. 2022;38(50):15766\u201375.","journal-title":"Langmuir"},{"issue":"1","key":"1894_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41467-022-35431-x","volume":"14","author":"S Li","year":"2023","unstructured":"Li S, Yu W, Xie F, Luo H, Liu Z, Lv W, Shi D, Yu D, Gao P, Chen C, et al. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat Commun. 2023;14(1):8.","journal-title":"Nat Commun"},{"key":"1894_CR8","doi-asserted-by":"publisher","first-page":"1002435","DOI":"10.3389\/fmed.2022.1002435","volume":"9","author":"S Cascinu","year":"2022","unstructured":"Cascinu S, Di Bartolomeo M, Lonardi S, Beretta G, Fornaro L, De Vita F. The evolving strategies for the management of patients with metastatic gastric cancer: a narrative review and expert opinion. Front Med (Lausanne). 2022;9:1002435.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"1894_CR9","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3390\/jcm12010223","volume":"12","author":"G Capriotti","year":"2022","unstructured":"Capriotti G, Piccardo A, Giovannelli E, Signore A. Targeting copper in cancer imaging and therapy: a new theragnostic agent. J Clin Med. 2022;12(1):652.","journal-title":"J Clin Med"},{"key":"1894_CR10","doi-asserted-by":"publisher","first-page":"1082691","DOI":"10.3389\/fgene.2022.1082691","volume":"13","author":"J Cai","year":"2022","unstructured":"Cai J, Xie H, Yan Y, Huang Z, Tang P, Cao X, Wang Z, Yang C, Wen J, Tan M, et al. A novel cuproptosis-related lncRNA signature predicts prognosis and therapeutic response in bladder cancer. Front Genet. 2022;13:1082691.","journal-title":"Front Genet"},{"issue":"10","key":"1894_CR11","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/j.bbamcr.2017.06.019","volume":"1864","author":"Abu El Maaty MA","year":"2017","unstructured":"Abu El Maaty MA. 1,25(OH)(2)D(3) disrupts glucose metabolism in prostate cancer cells leading to a truncation of the TCA cycle and inhibition of TXNIP expression. Biochim Biophys Acta Mol Cell Res. 2017;1864(10):1618\u201330.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"2","key":"1894_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s13238-017-0451-1","volume":"9","author":"NM Anderson","year":"2018","unstructured":"Anderson NM, Mucka P, Kern JG, Feng H. The emerging role and targetability of the TCA cycle in cancer metabolism. Protein Cell. 2018;9(2):216\u201337.","journal-title":"Protein Cell"},{"issue":"12","key":"1894_CR13","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3390\/jcm8122161","volume":"8","author":"J Marquez","year":"2019","unstructured":"Marquez J, Flores J, Kim AH, Nyamaa B, Nguyen ATT, Park N, Han J. Rescue of TCA cycle dysfunction for cancer therapy. J Clin Med. 2019;8(12):963.","journal-title":"J Clin Med"},{"issue":"3","key":"1894_CR14","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1002\/imt2.190","volume":"3","author":"W Chong","year":"2024","unstructured":"Chong W, Ren H, Chen H, Xu K, Zhu X, Liu Y, Sang Y, Li H, Liu J, Ye C, et al. Clinical features and molecular landscape of cuproptosis signature-related molecular subtype in gastric cancer. Imeta. 2024;3(3):e190.","journal-title":"Imeta"},{"issue":"6586","key":"1894_CR15","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, Rossen J, Joesch-Cohen L, Humeidi R, Spangler RD, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375(6586):1254\u201361.","journal-title":"Science"},{"key":"1894_CR16","first-page":"96","volume":"6","author":"X Lu","year":"2020","unstructured":"Lu X, Meng J, Zhou Y, Jiang L, Yan F. MOVICS: an R package for multi-omics integration and visualization in cancer subtyping. Bioinformatics. 2020;6:96.","journal-title":"Bioinformatics"},{"issue":"3","key":"1894_CR17","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (Camb). 2021;2(3):100141.","journal-title":"Innovation (Camb)"},{"issue":"5","key":"1894_CR18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/ng.3252","volume":"47","author":"K Schulze","year":"2015","unstructured":"Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47(5):505\u201311.","journal-title":"Nat Genet"},{"issue":"10","key":"1894_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1042\/BSR20211103","volume":"41","author":"JP Luo","year":"2021","unstructured":"Luo JP, Wang J, Huang JH. CDKN2A is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Biosci Rep. 2021;41(10):48.","journal-title":"Biosci Rep"},{"issue":"18","key":"1894_CR20","doi-asserted-by":"publisher","first-page":"6227","DOI":"10.1002\/cam4.4162","volume":"10","author":"C Zhang","year":"2021","unstructured":"Zhang C, Feng S, Tu Z, Sun J, Rui T, Zhang X, Huang H, Ling Q, Zheng S. Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome. Cancer Med. 2021;10(18):6227\u201338.","journal-title":"Cancer Med"},{"issue":"1","key":"1894_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13046-017-0618-x","volume":"36","author":"X Qin","year":"2017","unstructured":"Qin X, Li C, Guo T, Chen J, Wang HT, Wang YT, Xiao YS, Li J, Liu P, Liu ZS, et al. Upregulation of DARS2 by HBV promotes hepatocarcinogenesis through the miR-30e-5p\/MAPK\/NFAT5 pathway. J Exp Clin Cancer Res. 2017;36(1):148.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5145","key":"1894_CR22","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1126\/science.8278813","volume":"263","author":"MR Jackson","year":"1994","unstructured":"Jackson MR, Cohen-Doyle MF, Peterson PA, Williams DB. Regulation of MHC class I transport by the molecular chaperone, calnexin (p88, IP90). Science. 1994;263(5145):384\u20137.","journal-title":"Science"},{"issue":"3","key":"1894_CR23","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.4049\/jimmunol.166.3.1703","volume":"166","author":"G Diedrich","year":"2001","unstructured":"Diedrich G, Bangia N, Pan M, Cresswell P. A role for calnexin in the assembly of the MHC class I loading complex in the endoplasmic reticulum. J Immunol. 2001;166(3):1703\u20139.","journal-title":"J Immunol"},{"issue":"3","key":"1894_CR24","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/j.1460-2075.1994.tb06306.x","volume":"13","author":"KS Anderson","year":"1994","unstructured":"Anderson KS, Cresswell P. A role for calnexin (IP90) in the assembly of class II MHC molecules. EMBO J. 1994;13(3):675\u201382.","journal-title":"EMBO J"},{"issue":"10","key":"1894_CR25","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.neo.2019.07.002","volume":"21","author":"A Alam","year":"2019","unstructured":"Alam A, Taye N, Patel S, Thube M, Mullick J, Shah VK, Pant R, Roychowdhury T, Banerjee N, Chatterjee S, et al. SMAR1 favors immunosurveillance of cancer cells by modulating calnexin and MHC I expression. Neoplasia. 2019;21(10):945\u201362.","journal-title":"Neoplasia"},{"issue":"2","key":"1894_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41577-020-0390-6","volume":"21","author":"D Dersh","year":"2021","unstructured":"Dersh D, Holly J, Yewdell JW. A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. Nat Rev Immunol. 2021;21(2):116\u201328.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"1894_CR27","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1158\/2159-8290.CD-20-0812","volume":"11","author":"SS Gu","year":"2021","unstructured":"Gu SS, Zhang W, Wang X, Jiang P, Traugh N, Li Z, Meyer C, Stewig B, Xie Y, Bu X, et al. Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade. Cancer Discov. 2021;11(6):1524\u201341.","journal-title":"Cancer Discov"},{"issue":"2","key":"1894_CR28","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.apsb.2021.09.019","volume":"12","author":"D Du","year":"2022","unstructured":"Du D, Liu C, Qin M, Zhang X, Xi T, Yuan S, Hao H, Xiong J. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm Sin B. 2022;12(2):558\u201380.","journal-title":"Acta Pharm Sin B"},{"issue":"4","key":"1894_CR29","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/his.14014","volume":"76","author":"BK Masisi","year":"2020","unstructured":"Masisi BK, El Ansari R, Alfarsi L, Rakha EA, Green AR, Craze ML. The role of glutaminase in cancer. Histopathology. 2020;76(4):498\u2013508.","journal-title":"Histopathology"},{"issue":"5","key":"1894_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/1535370220908257","volume":"245","author":"L Barbier-Torres","year":"2020","unstructured":"Barbier-Torres L, Lu SC. Prohibitin 1 in liver injury and cancer. Exp Biol Med (Maywood). 2020;245(5):385\u201394.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"4","key":"1894_CR31","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/hep.28964","volume":"65","author":"W Fan","year":"2017","unstructured":"Fan W, Yang H, Liu T, Wang J, Li TW, Mavila N, Tang Y, Yang J, Peng H, Tu J, et al. Prohibitin 1 suppresses liver cancer tumorigenesis in mice and human hepatocellular and cholangiocarcinoma cells. Hepatology. 2017;65(4):1249\u201366.","journal-title":"Hepatology"},{"key":"1894_CR32","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.mito.2021.03.003","volume":"58","author":"AB Bandara","year":"2021","unstructured":"Bandara AB, Drake JC, James CC, Smyth JW, Brown DA. Complex I protein NDUFS2 is vital for growth, ROS generation, membrane integrity, apoptosis, and mitochondrial energetics. Mitochondrion. 2021;58:160\u20138.","journal-title":"Mitochondrion"},{"issue":"12","key":"1894_CR33","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1161\/CIRCRESAHA.118.314284","volume":"124","author":"KJ Dunham-Snary","year":"2019","unstructured":"Dunham-Snary KJ, Wu D, Potus F, Sykes EA, Mewburn JD, Charles RL, Eaton P, Sultanian RA, Archer SL. Ndufs2, a core subunit of mitochondrial complex I, is essential for acute oxygen-sensing and hypoxic pulmonary vasoconstriction. Circ Res. 2019;124(12):1727\u201346.","journal-title":"Circ Res"},{"issue":"3","key":"1894_CR34","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1074\/jbc.C112.436766","volume":"288","author":"DA Stroud","year":"2013","unstructured":"Stroud DA, Formosa LE, Wijeyeratne XW, Nguyen TN, Ryan MT. Gene knockout using transcription activator-like effector nucleases (TALENs) reveals that human NDUFA9 protein is essential for stabilizing the junction between membrane and matrix arms of complex I. J Biol Chem. 2013;288(3):1685\u201390.","journal-title":"J Biol Chem"},{"issue":"3","key":"1894_CR35","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/hep.28395","volume":"63","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Liu Y, Duan J, Yan H, Zhang J, Zhang H, Fan Q, Luo F, Yan G, Qiao K, et al. Hippocalcin-like 1 suppresses hepatocellular carcinoma progression by promoting p21(Waf\/Cip1) stabilization by activating the ERK1\/2-MAPK pathway. Hepatology. 2016;63(3):880\u201397.","journal-title":"Hepatology"},{"issue":"1","key":"1894_CR36","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s40425-019-0814-7","volume":"7","author":"J Ma","year":"2019","unstructured":"Ma J, Zheng B, Goswami S, Meng L, Zhang D, Cao C, Li T, Zhu F, Ma L, Zhang Z, et al. PD1(Hi) CD8(+) T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma. J Immunother Cancer. 2019;7(1):331.","journal-title":"J Immunother Cancer"},{"issue":"7652","key":"1894_CR37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60\u20135.","journal-title":"Nature"},{"issue":"11","key":"1894_CR38","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.it.2016.08.010","volume":"37","author":"KL Rock","year":"2016","unstructured":"Rock KL, Reits E, Neefjes J. Present yourself! by MHC Class I and MHC Class II molecules. Trends Immunol. 2016;37(11):724\u201337.","journal-title":"Trends Immunol"},{"issue":"11","key":"1894_CR39","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/jpm11111129","volume":"11","author":"F Tariq","year":"2021","unstructured":"Tariq F, Khan W, Ahmad W, Riaz SK, Khan M, Sherwani S, Haque S, Malik MFA, Iftikhar MJ, Khan S, et al. Effect of MHC linked 7-gene signature on delayed hepatocellular carcinoma recurrence. J Pers Med. 2021;11(11):96.","journal-title":"J Pers Med"},{"key":"1894_CR40","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2147\/JHC.S321919","volume":"8","author":"H Mai","year":"2021","unstructured":"Mai H, Chen J, Chen H, Liu Z, Huang G, Wang J, Xiao Q, Ren W, Zhou B, Hou J, et al. Fine mapping of the MHC region identifies novel variants associated with HBV-related hepatocellular carcinoma in Han Chinese. J Hepatocell Carcinoma. 2021;8:951\u201361.","journal-title":"J Hepatocell Carcinoma"},{"issue":"21","key":"1894_CR41","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.3748\/wjg.v11.i21.3297","volume":"11","author":"W Chen","year":"2005","unstructured":"Chen W, Cai MY, Wei DP, Wang X. Pivotal molecules of MHC I pathway in human primary hepatocellular carcinoma. World J Gastroenterol. 2005;11(21):3297\u20139.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1894_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-021-00995-8","volume":"14","author":"JY Hong","year":"2022","unstructured":"Hong JY, Cho HJ, Sa JK, Liu X, Ha SY, Lee T, Kim H, Kang W, Sinn DH, Gwak GY, et al. Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. Genome Med. 2022;14(1):1.","journal-title":"Genome Med"},{"issue":"4","key":"1894_CR43","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000515305","volume":"10","author":"CL Hsu","year":"2021","unstructured":"Hsu CL, Ou DL, Bai LY, Chen CW, Lin L, Huang SF, Cheng AL, Jeng YM, Hsu C. Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma. Liver Cancer. 2021;10(4):346\u201359.","journal-title":"Liver Cancer"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01894-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-025-01894-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01894-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T13:03:10Z","timestamp":1749733390000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-025-01894-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1894"],"URL":"https:\/\/doi.org\/10.1186\/s13148-025-01894-0","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"2 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical ApprovalNot applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}